2.https://newsroom.csl.com/2024-02-11-CSL-Announces-Top-line-Results-from-the-Phase-3-AEGIS-II-Trial-Evaluating-the-Efficacy-and-Safety-of-CSL112-apolipoprotein-A-I-human 3.C. Michael Gibson, et al. Rationale...
Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial...
Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA
https://doi.org/10.1161/CIRCULATIONAHA.116.025687 2.https://newsroom.csl.com/2024-02-11-CSL-Announces-Top-line-Results-from-the-Phase-3-AEGIS-II-Trial-Evaluating-the-Efficacy-and-Safety-of-CSL112-apolipoprotein-A-I...